Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 166

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer’s disease

Rijal Upadhaya, Ajeet, Kosterin, Irina, Kumar, Sathish, von Arnim, Christine A. F., Yamaguchi, Haruyasu, Fändrich, Marcus, Walter, Jochen, Thal, Dietmar Rudolf · 2014 · Brain

Abstract

Alzheimer's disease is characterized by the deposition of amyloid-β peptide in the brain. N-terminal truncation resulting in the formation of AβN3pE and phosphorylation at serine 8 have been reported to modify aggregation properties of amyloid-β. Biochemically, soluble, dispersible, membrane-associated, and insoluble, plaque-associated amyloid-β aggregates have been distinguished. Soluble and dispersible amyloid-β aggregates are both in mixture with the extracellular or intracellular fluid but dispersible aggregates can be cleared from proteins in solution by ultracentrifugation. To clarify the role of phosphorylated amyloid-β and AβN3pE in soluble, dispersible, membrane-associated, and plaque-associated amyloid-β aggregates in the pathogenesis of Alzheimer's disease we studied brains from 21 cases with symptomatic Alzheimer's disease, 33 pathologically preclinical Alzheimer's disease cases, and 20 control cases. Western blot analysis showed that soluble, dispersible, membrane-associated and plaque-associated amyloid-β aggregates in the earliest preclinical stage of Alzheimer's disease did not exhibit detectable amounts of AβN3pE and phosphorylated amyloid-β. This stage was referred to as biochemical stage 1 of amyloid-β aggregation and accumulation. In biochemical amyloid-β stage 2, AβN3pE was additionally found whereas phosphorylated amyloid-β was restricted to biochemical amyloid-β stage 3, the last stage of amyloid-β aggregation. Phosphorylated amyloid-β was seen in the dispersible, membrane-associated, and plaque-associated fraction. All cases with symptomatic Alzheimer's disease in our sample fulfilled biochemical amyloid-β stage 3 criteria, i.e. detection of phosphorylated amyloid-β. Most, but not all, cases with pathologically preclinical Alzheimer's disease had biochemical amyloid-β stages 1 or 2. Immunohistochemistry confirmed the hierarchical occurrence of amyloid-β, AβN3pE, and phosphorylated amyloid-β in amyloid plaques. Phosphorylated amyloid-β containing plaques were, thereby, seen in all symptomatic cases with Alzheimer's disease but only in a few non-demented control subjects. The biochemical amyloid-β stages correlated with the expansion of amyloid-β plaque deposition and with that of neurofibrillary tangle pathology. Taken together, we demonstrate that AβN3pE and phosphorylated amyloid-β are not only detectable in plaques, but also in soluble and dispersible amyloid-β aggregates outside of plaques. They occur in a hierarchical sequence that allows the distinction of three stages. In light of our findings, it is tempting to speculate that this hierarchical, biochemical sequence of amyloid-β aggregation and accumulation is related to disease progression and may be relevant for an increasing toxicity of amyloid-β aggregates.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awt362

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 20

  1. Alzheimer, 1907, Ueber eine eigenartige Erkrankung der Hirnrinde, Allg Zschr Psych, 64, 146
  2. Andorfer, 2000, PKA phosphorylations on tau: developmental studies in the mouse, Dev Neurosci, 22, 303, 10.1159/000017454 · DOI
  3. Arriagada, 1992, Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease, Neurology, 42, 1681, 10.1212/WNL.42.9.1681 · DOI · Paper page
  4. Dickson, 2011, Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau), J Mol Neurosci, 45, 384, 10.1007/s12031-011-9589-0 · DOI · Paper page
  5. Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol, 6, 734, 10.1016/S1474-4422(07)70178-3 · DOI · Paper page
  6. Habicht, 2007, Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils, Proc Natl Acad Sci USA, 104, 19232, 10.1073/pnas.0703793104 · DOI · Paper page
  7. Harper, 1997, Observation of metastable Abeta amyloid protofibrils by atomic force microscopy, Chem Biol, 4, 119, 10.1016/S1074-5521(97)90255-6 · DOI · Paper page
  8. Iwatsubo, 1996, Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques, Am J Pathol, 149, 1823
  9. Kim, 1988, Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide, Neurosci Res Commun, 2, 121
  10. Kumar, 2011, Extracellular phosphorylation of the amyloid beta-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease, EMBO J, 30, 2255, 10.1038/emboj.2011.138 · DOI · Paper page
  11. Kumar, 2013, Early intraneuronal accumulation and increased aggregation of phosphorylated Abeta in a mouse model of Alzheimer's disease, Acta Neuropathol, 125, 699, 10.1007/s00401-013-1107-8 · DOI
  12. Masters, 1985, Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels, EMBO J, 4, 2757, 10.1002/j.1460-2075.1985.tb04000.x · DOI · Paper page
  13. Mc Donald, 2010, The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia, Brain, 133, 1328, 10.1093/brain/awq065 · DOI · Paper page
  14. Monsell, 2013, Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology, Neurology, 80, 2121, 10.1212/WNL.0b013e318295d7a1 · DOI
  15. Rijal Upadhaya, 2012, Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice, Neurobiol Aging, 33, 2641, 10.1016/j.neurobiolaging.2011.12.032 · DOI
  16. Rijal Upadhaya, 2012, High-molecular weight Aβ-oligomers and protofibrils are the predominant Aβ-species in the native soluble protein fraction of the AD brain, J Cell Mol Med, 16, 287, 10.1111/j.1582-4934.2011.01306.x · DOI
  17. Schlenzig, 2009, Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides, Biochemistry, 48, 7072, 10.1021/bi900818a · DOI · Paper page
  18. Thal, 2013, Pathology of clinical and preclinical Alzheimer's disease, Eur Arch Psychiatry Clin Neurosci, 263, S137, 10.1007/s00406-013-0449-5 · DOI
  19. Walsh, 1997, Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate, J Biol Chem, 272, 22364, 10.1074/jbc.272.35.22364 · DOI · Paper page
  20. Watt, 2013, Oligomers, fact or artefact? SDS-PAGE induces dimerization of beta-amyloid in human brain samples, Acta Neuropathol, 125, 549, 10.1007/s00401-013-1083-z · DOI

Cited by

See all 166

Metadata

Authors
Rijal Upadhaya, A., Kosterin, I., Kumar, S., von Arnim, C. A. F., Yamaguchi, H., Fändrich, M., Walter, J., & Thal, D. R.
Venue
Brain
Published
2014-02-10
Volume
137
Issue
3
Pages
887-903
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2154735761
Cited by
166
References
23
FWCI
7.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.